Quetiapine in patients with borderline personality disorder and psychosis: A case series

International Journal of Psychiatry in Clinical Practice

Volumn 9, Issue 3, 2005, Pages 180-186

  Gruettert, Torsten ^a   Friege, Lars ^b  

^a Florence Nightingale Krankenhaus   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Atypical antipsychotics; Borderline personality disorder; Efficacy; Psychotic symptoms; Quetiapine

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROTHIXENE; LEVOMEPROMAZINE; PERAZINE; PROMETHAZINE; QUETIAPINE;

ADULT; ARTICLE; AUTOMUTILATION; BARRAT IMPULSIVENESS SCALE; BORDERLINE STATE; CASE STUDY; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HOSPITALIZATION; HUMAN; IMPULSIVENESS; PRIORITY JOURNAL; PSYCHOSIS; RANK SUM TEST; RATING SCALE; SOMNOLENCE; STATISTICAL ANALYSIS; SUBSTANCE ABUSE; SYMPTOM; SYMPTOM CHECKLIST 90;

EID: 27144511737     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500510029048     Document Type: Article

References (40)

1. Stern A. Borderline group of neurosis. Psychoanal Q 1938;7: 467-89.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
3. Skodol AE, Gunderson JG, Pfohl B, et al. The borderline diagnosis I: Psychopathology, comorbidity, and personality structure. Biol Psychiatry 2002;51:936-50.
4. Stone MH, Hurt SW, Stone DK. The PI 500: Long-term follow-up of borderline inpatients meetings DSM-III criteria: I. Global outcome. J Personal Disord 1987;1:291-8.
5. Jerschke S, Meixner K, Richter H, et al. The treatment history of patients with borderline personality disorder in the Republic of Germany. Fortschr Neurol Psychiatr 1998;66: 545-52.
6. Linehan MM. Parasuicidal borderline patients. Arch Gen Psychiatry 1993;50:971-4.
7. Spitzer RL, Endicott J, Gibbon M. Crossing the border into borderline personality and borderline schizophrenia. The development of criteria. Arch Gen Psychiatry 1979;36:17-24.
8. Katzow JJ, Hsu DJ, Ghaemi SN. The bipolar spectrum: A clinical perspective. Bipolar Disord 2003;5:436-42.
9. Tramantano G, Javier RA, Colon M. Discriminating among subgroups of borderline personality disorder: An assessment of object representations. Am J Psychoanal 2003;63:149-75.
10. Livesley WJ, Lang KL, Vernon PA. Phenotypic and genetic structure of traits delineating personality disorder. Arch Gen Psychiatry 1998;55:941-8.
11. Silk KR. Overview of biologic factors. Psychiatr Clin North Am 2000;23:61-75.
12. Perugi G, Akiskal HS. The soft bipolar spectrum redefined: Focus on the cyclothymic, anxious-sensitive, impulse-dyscontrol, and binge-eating connection in bipolar II and related conditions. Psychiatr Clin North Am 2002;25:713-37.
13. Schmahl C, Bohus M. Symptom-focused drug therapy in borderline personality disorder. Fortschr Neurol Psychiatr 2001;69:310-21.
14. Newton-Howes G, Tyrer P. Pharmacotherapy for personality disorders. Expert Opin Pharmacother 2003;4:1643-9.
15. American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry 2001;158:1-52.
16. Rocca P, Marchiaro L, Cocuzza E, et al. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002;63:241-4.
17. Markovitz PJ. Recent trends in the pharmacotherapy of personality disorders. J Personal Disord 2004;18:90-101.
18. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001; 62:849-54.
19. Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004;65:104-9.
20. Khouzam HR, Donnelly NJ. Remission of self mutilation in a patient with borderline personality during risperidone therapy. J Nerv Ment Dis 1997;185:348-9.
21. Tuinier S, Verhoeven WMA, Marijnissen GM, et al. The effects of risperidone in severe depersonalization and derealization in the context of borderline personality disorder. Eur Neuropsychopharmacol 1997;7:283.
22. Hallmayer JF. Risperidone and borderline personality disorder. Curr Psychiatry Rep 2003;5:175-6.
23. Kasper S, Müller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother 2000;1:783-801.
24. Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002;53:239-48.
25. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66:111-21.
26. Calabrese J, Macfadden W, McCoy R, et al. Double-blind, placebo-controlled study of quetiapine in bipolar depression. Presented at the 157th Annual Meeting of the American Psychiatric Association. New York, USA, May 1-6, 2004.
27. Arvanitis LA, Miller BG, the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biol Psychiatry 1997; 42:233-46.
28. Kasper S, Tauscher J, Heiden A. Quetiapine: Efficacy and tolerability in schizophrenia. Eur Neuropsychopharmacol 2001;11(Suppl 4):S405-13.
29. Brecher M, Rak IW, Melvin K, et al. The long-term effect of quetiapine (SeroquelTM) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000;4:287-91.
30. Zanarini MC, Gunderson JG, Frankenburg FR, et al. The revised diagnostic interview for borderlines: Discriminating BPD from other Axis II disorders. J Personal Disord 1989;3: 10-8.
31. Guy W. CGI @Clinical Global Impressions. Assessment manual for psychopharmacology - revised. DHEW Publ No ADM 76-338. Rockville, MD: US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. p 217-22.
32. Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33: 766-71.
33. Barrat ES. Factor analysis of some psychometric measures of impulsiveness and anxiety. Psychol Rep 1965;16:547-54.
34. Derogatis LR, Lipman RS, Covi L. SCL-90: An outpatient psychiatric rating scale - Preliminary report. Psychopharmacol Bull 1973;9:13-28.
35. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
36. Cagno S. Quetiapine and borderline personality disorder: a clinical experience. Treatment of a short psychotic episode]. Riv Psichiatria 2001;36:344-8.
37. Hilger E, Barnas C, Kasper S. Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry 2003;4:42-4.
38. Adityanjee MD. Quetiapine in reducing the symptoms of borderline personality disorder. Poster presented at the International Congress on Schizophrenia Research, Colorado Springs, CO, USA, 29 March-2 April, 2003.
39. Villeneuve E, Lemelin S. Quetiapine treatment of boderline personality disorder. Poster presented at the 4th International Forum on Mood and Anxiety Disorders, Monte Carlo, Monaco, 19-21 November, 2003.
40. Lemelin S, Guimond S, Villeneuve E. Impact of quetiapine on attentional functioning in borderline personality disorder patients. Poster presented at the 53rd Annual Meeting of the Canadian Psychiatric Association, Halifax, Nova Scotia, Canada, 30 October-2 November, 2003.